PRPH - ProPhase Labs Inc logo

ProPhase Labs Inc

PRPH

ProPhase Labs develops and commercializes drugs, dietary supplements, and diagnostics. It offers products for male enhancement and energy, cancer diagnostic tests, genome sequencing services, and COVID-19 testing, catering to both consumers and healthcare providers.

โš•๏ธ Healthcare NASDAQ Listed 1997 $ USD
$1,000 invested 30 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth-53.58%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-27.36%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.2
Net Growth-460.94%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-96.01%
Rev Trend20%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-5x
Net Trend50%
Net Income Consistency
Rev Growth-84.98%
Rev Trend40%
Revenue Consistency
20 Years
Score2.3
Net Growth-10x
Net Trend60%
Net Income Consistency
Rev Growth-92.51%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth-207.82%
Net Trend52%
Net Income Consistency
Rev Growth-95.50%
Rev Trend45%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where ProPhase Labs Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • PRPH

2008: 98.8% ยท 2021: 64.1% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 0.01โ€”
1 Year2025-09-29
$ 4.38-99.77%
5 Years2021-09-29
$ 46.68-99.98%
10 Years2016-09-29
$ 8.49-99.88%
20 Years2006-09-29
$ 31.96-99.97%
30 Years1996-09-27
$ 10.85-99.91%
All Time1997-01-16
$ 51.06-99.98%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 3M-$ 22M$ 20K
2025$ 4M-$ 14M$ 90K
2024$ 6M-$ 53M$ 678K
2023$ 44M-$ 16M$ 4M
2022$ 122M$ 18M$ 17M
2021$ 79M$ 6M$ 17M
2020$ 14M-$ 2M$ 8M
2019$ 9M-$ 3M$ 1M
2018$ 13M-$ 1M$ 8M
2017$ 9M$ 41M$ 21M
2016$ 21M-$ 2M$ 441K
2015$ 20M-$ 3M$ 1M
2014$ 22M-$ 7M$ 2M
2013$ 25M$ 405K$ 1M
2012$ 22M-$ 1M$ 572K
2011$ 17M-$ 2M$ 5M
2010$ 14M-$ 3M$ 8M
2009$ 19M-$ 3M$ 12M
2008$ 20M-$ 5M$ 11M
2007$ 39M-$ 2M$ 16M
2006$ 42M-$ 1M$ 17M
2005$ 53M$ 3M$ 16M
2004$ 43M$ 452.86K$ 14M
2003$ 41M$ 674.57K$ 11M
2002$ 29M-$ 6M$ 12M
2001$ 24M$ 215.96K$ 9M
2000$ 19M-$ 5M$ 11M
1999$ 24M-$ 4M$ 14M
1998$ 36M$ 6M$ 28M
IPO1997$ 70M$ 21M$ 25M
PRPH - ProPhase Labs Inc logo

ProPhase Labs Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 14M to $ 4M and net income went from -$ 2M to -$ 14M. Revenue increased in 1 of those 5 years; net income in 2.

Across ProPhase Labs Inc's full reported history, from 1997 to 2025, revenue declined from $ 70M to $ 4M and net income went from $ 21M to -$ 14M. Revenue increased in 45% of the years measured; net income in 52%.

ProPhase Labs Inc currently holds a 20-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.

Membership

Continue PRPHโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies